Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in IgG4-Related Disease
NCT07025330Phase 2Active, not recruiting
- Sponsor
- Stanford University
- Start
- Nov 2025
- Primary completion
- Mar 2028
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 2 trial of efgartigimod alfa in IgG4-related disease (IgG4-RD), sponsored by Stanford University. Started Nov 2025; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07025330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025330.